ALXN1840 shows rapid and sustained improvement in copper mobilisation from tissues, potentially closing treatment gaps for Wilson disease community
FoCus Phase III trial evaluates new approach to copper mobilisation for patients with Wilson disease who have not seen meaningful innovation in decades.In Wilson disease, excess copper build-up in organs and tissues can lead to liver disease as well as neurological and psychiatric symptoms.Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN1840, an investigational once-daily, oral medicine, met its primary endpoint demonstrating three-times greater copper mobilisation from tissues compared to the standard of care (SoC) arm (Least Square Mean